Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous engineered TCR-T cells KSX01

A preparation of autologous T lymphocytes genetically modified to express a T-cell receptor (TCR) specific for an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a TCR specific for the TAA, and expanded ex-vivo. Upon reintroduction into the patient, the autologous engineered TCR-T cells KSX01 target and bind to tumor cells expressing the TAA, which may induce cell death in and halt the growth of cancer cells expressing the undisclosed TAA.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	TCR-T cells KSX01
Code name:	KSX 01 KSX-01 KSX01

autologous engineered TCR-T cells KSX01

Search NCI's Drug Dictionary